Free Trial

Capricor Therapeutics (CAPR) Financials

Capricor Therapeutics logo
$13.28 +0.13 (+0.99%)
As of 04/24/2025 04:00 PM Eastern
Annual Income Statements for Capricor Therapeutics

Annual Income Statements for Capricor Therapeutics

This table shows Capricor Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
-29 -22 -40
Consolidated Net Income / (Loss)
-29 -22 -40
Net Income / (Loss) Continuing Operations
-29 -22 -40
Total Pre-Tax Income
-29 -22 -40
Total Operating Income
-30 -24 -43
Total Gross Profit
2.55 25 22
Total Revenue
2.55 25 22
Operating Revenue
2.55 25 22
Total Cost of Revenue
0.00 0.00 0.00
Total Operating Expenses
32 49 65
Selling, General & Admin Expense
10 13 15
Research & Development Expense
22 36 50
Other Special Charges / (Income)
0.03 0.01 0.11
Total Other Income / (Expense), net
0.71 1.79 2.10
Interest & Investment Income
0.52 1.73 2.20
Other Income / (Expense), net
0.19 0.07 0.01
Basic Earnings per Share
($1.18) ($0.83) ($1.15)
Weighted Average Basic Shares Outstanding
24.55M 26.78M 35.22M
Diluted Earnings per Share
($1.18) ($0.83) ($1.15)
Weighted Average Diluted Shares Outstanding
24.55M 26.78M 35.22M
Weighted Average Basic & Diluted Shares Outstanding
25.26M 31.40M 45.68M

Quarterly Income Statements for Capricor Therapeutics

This table shows Capricor Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders
-6.37 -7.72 -7.77 -7.37 -6.46 -0.70 -9.79 -11 -13 -7.06
Consolidated Net Income / (Loss)
-6.37 -7.72 -7.77 -7.37 -6.39 -0.76 -9.79 -11 -13 -7.12
Net Income / (Loss) Continuing Operations
-6.37 -7.69 -7.77 -7.37 -6.39 -0.77 -9.79 -11 -13 -7.00
Total Pre-Tax Income
-6.37 -7.69 -7.77 -7.37 -6.39 -0.77 -9.79 -11 -13 -7.00
Total Operating Income
-6.48 -8.07 -8.18 -7.75 -6.86 -1.28 -10 -12 -13 -7.70
Total Gross Profit
1.59 0.96 2.99 3.92 6.19 12 4.91 3.97 2.26 11
Total Revenue
1.59 0.96 2.99 3.92 6.19 12 4.91 3.97 2.26 11
Operating Revenue
1.59 - 2.99 3.92 6.19 12 4.91 3.97 2.26 11
Total Operating Expenses
8.07 9.06 11 12 13 13 15 16 15 19
Selling, General & Admin Expense
2.56 2.79 3.51 2.85 3.02 3.43 4.07 3.06 3.46 4.27
Research & Development Expense
5.50 6.23 7.66 8.82 10 9.94 11 13 12 15
Total Other Income / (Expense), net
0.11 0.38 0.42 0.38 0.47 0.52 0.47 0.59 0.45 0.58
Interest & Investment Income
0.11 0.38 0.42 0.38 0.48 0.45 0.47 0.59 0.45 0.69
Basic Earnings per Share
($0.26) ($0.31) ($0.31) ($0.29) ($0.25) $0.02 ($0.31) ($0.35) ($0.38) ($0.11)
Weighted Average Basic Shares Outstanding
24.43M 24.55M 25.25M 25.34M 25.82M 26.78M 31.35M 31.84M 33.09M 35.22M
Diluted Earnings per Share
($0.26) ($0.31) ($0.31) ($0.29) ($0.25) $0.02 ($0.31) ($0.35) ($0.38) ($0.11)
Weighted Average Diluted Shares Outstanding
24.43M 24.55M 25.25M 25.34M 25.82M 26.78M 31.35M 31.84M 33.09M 35.22M
Weighted Average Basic & Diluted Shares Outstanding
25.24M 25.26M 25.27M 25.78M 30.79M 31.40M 31.81M 32.54M 45.47M 45.68M

Annual Cash Flow Statements for Capricor Therapeutics

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Net Change in Cash & Equivalents
-25 5.09 -3.41
Net Cash From Operating Activities
4.92 -26 -40
Net Cash From Continuing Operating Activities
4.92 -26 -40
Net Income / (Loss) Continuing Operations
-29 -22 -40
Consolidated Net Income / (Loss)
-29 -22 -40
Depreciation Expense
0.53 1.07 1.43
Non-Cash Adjustments To Reconcile Net Income
4.50 -2.45 9.83
Changes in Operating Assets and Liabilities, net
29 -1.93 -11
Net Cash From Investing Activities
-35 5.11 -116
Net Cash From Continuing Investing Activities
-35 5.11 -116
Purchase of Property, Plant & Equipment
-2.00 -1.31 -1.17
Purchase of Investments
-114 -97 -208
Sale and/or Maturity of Investments
83 105 94
Other Investing Activities, net
-1.36 -0.74 -0.37
Net Cash From Financing Activities
4.87 26 153
Net Cash From Continuing Financing Activities
4.87 26 153
Issuance of Common Equity
4.80 26 152
Other Financing Activities, net
0.07 0.06 0.45
Cash Interest Paid
0.00 0.00 0.00
Cash Income Taxes Paid
0.00 0.00 0.00

Quarterly Cash Flow Statements for Capricor Therapeutics

This table details how cash moves in and out of Capricor Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents
-7.98 1.19 1.00 -0.77 -0.85 5.71 -8.48 4.47 58 -57
Net Cash From Operating Activities
-5.69 -6.90 4.21 -9.42 -8.79 -12 -1.27 -12 -12 -15
Net Cash From Continuing Operating Activities
-5.69 -6.90 4.21 -9.42 -8.79 -12 -1.27 -12 -12 -15
Net Income / (Loss) Continuing Operations
-6.37 -7.72 -7.77 -7.37 -6.39 -0.76 -9.79 -11 -13 -7.12
Consolidated Net Income / (Loss)
-6.37 -7.72 -7.77 -7.37 -6.39 -0.76 -9.79 -11 -13 -7.12
Depreciation Expense
0.14 0.19 0.23 0.25 0.28 0.31 0.33 0.36 0.36 0.38
Non-Cash Adjustments To Reconcile Net Income
1.11 1.18 2.19 1.61 1.72 -7.97 13 2.14 2.00 -7.57
Changes in Operating Assets and Liabilities, net
-0.56 -0.55 9.56 -3.92 -4.40 -3.17 -5.06 -3.79 -1.45 -0.49
Net Cash From Investing Activities
-4.18 5.14 -3.21 6.46 7.72 -5.86 -9.50 15 2.00 -123
Net Cash From Continuing Investing Activities
-4.18 5.14 -3.21 6.46 7.72 -5.86 -9.50 15 2.00 -123
Purchase of Property, Plant & Equipment
-0.56 -0.69 -0.35 -0.14 -0.27 -0.56 -0.61 -0.06 -0.01 -0.49
Purchase of Investments
-33 -32 -35 -18 -20 -25 -33 -16 -20 -139
Sale and/or Maturity of Investments
30 38 32 25 28 20 24 31 22 17
Other Investing Activities, net
-0.54 -0.53 -0.11 -0.10 -0.36 -0.17 -0.06 -0.02 -0.05 -0.25
Net Cash From Financing Activities
1.88 2.95 0.00 2.19 0.22 23 2.29 2.07 67 81
Net Cash From Continuing Financing Activities
1.88 2.95 0.00 2.19 0.22 23 2.29 2.07 67 81
Issuance of Common Equity
1.88 2.92 0.00 2.13 0.22 23 2.29 1.99 67 81
Other Financing Activities, net
0.00 0.03 0.00 0.06 - 0.00 0.00 0.08 0.12 0.25

Annual Balance Sheets for Capricor Therapeutics

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2022 2023 2024
Total Assets
50 59 170
Total Current Assets
43 51 163
Cash & Equivalents
9.60 15 11
Short-Term Investments
32 25 140
Prepaid Expenses
0.92 1.00 1.50
Other Current Assets
0.55 10 10
Plant, Property, & Equipment, net
4.59 5.56 5.56
Total Noncurrent Assets
2.35 2.32 1.53
Other Noncurrent Operating Assets
2.35 2.32 1.53
Total Liabilities & Shareholders' Equity
50 59 170
Total Liabilities
38 36 25
Total Current Liabilities
24 31 21
Accounts Payable
4.83 6.25 8.19
Current Deferred Revenue
18 24 12
Other Current Liabilities
0.77 0.75 0.83
Total Noncurrent Liabilities
15 4.86 3.99
Other Noncurrent Operating Liabilities
1.88 4.86 3.99
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
12 23 145
Total Preferred & Common Equity
12 23 145
Preferred Stock
0.00 0.00 0.00
Total Common Equity
12 23 145
Common Stock
149 182 344
Retained Earnings
-137 -159 -200
Accumulated Other Comprehensive Income / (Loss)
0.11 0.24 1.03

Quarterly Balance Sheets for Capricor Therapeutics

This table presents Capricor Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets
54 54 46 37 49 38 93
Total Current Assets
48 47 39 30 41 31 86
Cash & Equivalents
8.41 11 9.84 8.98 6.21 11 68
Short-Term Investments
38 35 28 20 34 19 17
Prepaid Expenses
0.34 0.88 0.58 0.46 1.13 0.84 0.39
Other Current Assets
0.55 0.55 0.55 0.55 0.37 0.37 0.41
Plant, Property, & Equipment, net
3.59 4.81 4.79 5.14 5.89 5.62 5.32
Total Noncurrent Assets
2.83 2.19 2.03 2.49 1.85 1.99 1.81
Other Noncurrent Operating Assets
2.83 2.19 2.03 2.49 1.85 1.99 1.81
Total Liabilities & Shareholders' Equity
54 54 46 37 49 38 93
Total Liabilities
39 48 43 39 31 27 25
Total Current Liabilities
23 37 35 33 26 22 20
Accounts Payable
3.94 5.41 5.13 6.77 6.25 6.17 6.53
Current Deferred Revenue
19 31 29 25 19 15 13
Other Current Liabilities
0.70 0.69 0.71 0.75 0.77 0.79 0.81
Total Noncurrent Liabilities
15 11 8.13 6.01 4.63 4.42 4.21
Long-Term Debt
3.38 3.38 3.38 3.38 3.38 3.38 3.38
Other Noncurrent Operating Liabilities
2.08 1.70 1.52 1.68 1.25 1.04 0.83
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
15 6.21 2.73 -1.79 18 12 68
Total Preferred & Common Equity
15 6.21 2.73 -1.79 18 12 68
Preferred Stock
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity
15 6.21 2.73 -1.79 18 12 68
Common Stock
145 151 155 157 187 192 261
Retained Earnings
-129 -145 -152 -159 -169 -180 -193
Accumulated Other Comprehensive Income / (Loss)
0.12 0.09 0.18 0.11 0.31 0.15 0.10

Annual Metrics and Ratios for Capricor Therapeutics

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric 2022 2023 2024
Growth Metrics
- - -
Revenue Growth
941.85% 886.81% -11.55%
EBITDA Growth
-46.14% 20.82% -79.29%
EBIT Growth
-47.00% 18.63% -77.25%
NOPAT Growth
-41.83% 18.92% -76.78%
Net Income Growth
-44.93% 23.20% -81.57%
EPS Growth
-35.63% 29.66% -38.55%
Operating Cash Flow Growth
129.25% -620.61% -56.25%
Free Cash Flow Firm Growth
129.99% -573.31% -53.34%
Invested Capital Growth
-18,707.00% 36.34% 64.15%
Revenue Q/Q Growth
60.31% 79.20% -4.12%
EBITDA Q/Q Growth
-5.01% 23.30% -18.23%
EBIT Q/Q Growth
-5.34% 22.20% -17.73%
NOPAT Q/Q Growth
-6.02% 21.98% -17.75%
Net Income Q/Q Growth
-5.57% 23.79% -18.63%
EPS Q/Q Growth
-4.42% 28.45% -12.75%
Operating Cash Flow Q/Q Growth
-20.59% -22.44% -8.70%
Free Cash Flow Firm Q/Q Growth
36.53% -17.85% -4.58%
Invested Capital Q/Q Growth
4.62% 37.30% 54.78%
Profitability Metrics
- - -
Gross Margin
100.00% 100.00% 100.00%
EBITDA Margin
-1,135.57% -91.12% -184.69%
Operating Margin
-1,163.93% -95.63% -191.13%
EBIT Margin
-1,156.46% -95.36% -191.09%
Profit (Net Income) Margin
-1,137.37% -88.52% -181.71%
Tax Burden Percent
100.12% 100.00% 100.28%
Interest Burden Percent
98.23% 92.83% 94.82%
Effective Tax Rate
0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00%
Return on Equity (ROE)
-134.49% -129.63% -48.16%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-64.55% -44.12% -37.13%
Return on Assets (ROA)
-63.48% -40.96% -35.31%
Return on Common Equity (ROCE)
-134.49% -129.63% -48.16%
Return on Equity Simple (ROE_SIMPLE)
-246.22% -98.61% -27.82%
Net Operating Profit after Tax (NOPAT)
-21 -17 -30
NOPAT Margin
-814.75% -66.94% -133.79%
Net Nonoperating Expense Percent (NNEP)
-23.58% -13.97% -11.17%
Return On Investment Capital (ROIC_SIMPLE)
- -74.57% -20.48%
Cost of Revenue to Revenue
0.00% 0.00% 0.00%
SG&A Expenses to Revenue
408.86% 50.87% 66.76%
R&D to Revenue
855.07% 144.76% 224.37%
Operating Expenses to Revenue
1,265.28% 195.65% 291.63%
Earnings before Interest and Taxes (EBIT)
-30 -24 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-29 -23 -41
Valuation Ratios
- - -
Price to Book Value (P/BV)
8.27 6.66 4.31
Price to Tangible Book Value (P/TBV)
8.27 6.66 4.31
Price to Revenue (P/Rev)
38.19 5.98 28.18
Price to Earnings (P/E)
0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
23.28 4.41 21.37
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
12.08 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
10.61 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.29 0.00 0.00
Long-Term Debt to Equity
0.29 0.00 0.00
Financial Leverage
-1.62 -2.26 -1.14
Leverage Ratio
2.12 3.16 1.36
Compound Leverage Factor
2.08 2.94 1.29
Debt to Total Capital
22.27% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
22.27% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
77.73% 100.00% 100.00%
Debt to EBITDA
-0.12 0.00 0.00
Net Debt to EBITDA
1.31 0.00 0.00
Long-Term Debt to EBITDA
-0.12 0.00 0.00
Debt to NOPAT
-0.16 0.00 0.00
Net Debt to NOPAT
1.83 0.00 0.00
Long-Term Debt to NOPAT
-0.16 0.00 0.00
Altman Z-Score
-3.74 -1.82 13.72
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
1.82 1.63 7.77
Quick Ratio
1.76 1.26 7.21
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
5.60 -26 -41
Operating Cash Flow to CapEx
245.80% -1,951.46% -3,427.61%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00
Efficiency Ratios
- - -
Asset Turnover
0.06 0.46 0.19
Accounts Receivable Turnover
0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00
Fixed Asset Turnover
0.80 4.96 4.00
Accounts Payable Turnover
0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00
Capital & Investment Metrics
- - -
Invested Capital
-27 -17 -6.05
Invested Capital Turnover
-0.19 -1.16 -1.94
Increase / (Decrease) in Invested Capital
-26 9.64 11
Enterprise Value (EV)
59 111 476
Market Capitalization
97 151 627
Book Value per Share
$0.47 $0.73 $3.20
Tangible Book Value per Share
$0.47 $0.73 $3.20
Total Capital
15 23 145
Total Debt
3.38 0.00 0.00
Total Long-Term Debt
3.38 0.00 0.00
Net Debt
-38 -39 -152
Capital Expenditures (CapEx)
2.00 1.31 1.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-22 -20 -9.16
Debt-free Net Working Capital (DFNWC)
19 20 142
Net Working Capital (NWC)
19 20 142
Net Nonoperating Expense (NNE)
8.23 5.43 11
Net Nonoperating Obligations (NNO)
-38 -39 -152
Total Depreciation and Amortization (D&A)
0.53 1.07 1.43
Debt-free, Cash-free Net Working Capital to Revenue
-866.92% -79.05% -41.12%
Debt-free Net Working Capital to Revenue
756.51% 77.79% 639.23%
Net Working Capital to Revenue
756.51% 77.79% 639.23%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
($1.18) ($0.83) ($1.15)
Adjusted Weighted Average Basic Shares Outstanding
24.55M 26.78M 35.22M
Adjusted Diluted Earnings per Share
($1.18) ($0.83) ($1.15)
Adjusted Weighted Average Diluted Shares Outstanding
24.55M 26.78M 35.22M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
25.26M 31.40M 45.68M
Normalized Net Operating Profit after Tax (NOPAT)
-21 -17 -30
Normalized NOPAT Margin
-813.81% -66.92% -133.43%
Pre Tax Income Margin
-1,136.02% -88.52% -181.20%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Capricor Therapeutics

This table displays calculated financial ratios and metrics derived from Capricor Therapeutics' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics
- - - - - - - - - -
Revenue Growth
0.00% 0.00% 0.00% 0.00% 288.66% 1,159.30% 64.29% 1.38% -63.44% -7.92%
EBITDA Growth
-63.31% -24.98% -2.79% -6.74% -3.90% 87.64% -24.89% -49.94% -91.99% -652.00%
EBIT Growth
-64.10% -26.44% -4.51% -8.64% -5.97% 84.12% -25.43% -49.62% -89.52% -500.79%
NOPAT Growth
-50.14% -26.44% -4.51% -5.81% -5.97% 84.12% -25.43% -49.62% -89.52% -500.79%
Net Income Growth
-62.04% -24.72% 0.64% -3.62% -0.31% 90.13% -26.08% -49.32% -96.49% -833.83%
EPS Growth
-52.94% -19.23% 3.13% 0.00% 3.85% 106.45% 0.00% -20.69% -52.00% -650.00%
Operating Cash Flow Growth
-70.33% -22.65% -82.49% -43.95% -54.69% -67.98% -130.13% -30.48% -32.38% -27.62%
Free Cash Flow Firm Growth
649.18% 344.78% -101.05% -114.27% -129.64% -150.81% -11,883.28% -816.52% -298.59% -53.93%
Invested Capital Growth
-577.78% -18,707.00% -18.22% -9.02% 3.16% 36.34% 48.66% 54.36% 50.29% 64.15%
Revenue Q/Q Growth
0.00% -39.69% 211.15% 31.16% 57.90% 95.42% -59.41% -19.06% -43.05% 392.14%
EBITDA Q/Q Growth
9.67% -24.19% -1.01% 5.81% 12.07% 85.22% -920.30% -13.08% -12.59% 42.11%
EBIT Q/Q Growth
9.16% -24.52% -1.47% 5.34% 11.39% 81.33% -701.21% -12.91% -12.24% 40.83%
NOPAT Q/Q Growth
11.53% -24.52% -1.47% 5.34% 11.39% 81.33% -701.21% -12.91% -12.24% 40.83%
Net Income Q/Q Growth
10.38% -21.19% -0.61% 5.17% 13.25% 88.07% -1,185.16% -12.31% -14.15% 43.32%
EPS Q/Q Growth
10.34% -19.23% 0.00% 6.45% 13.79% 108.00% -1,650.00% -12.90% -8.57% 71.05%
Operating Cash Flow Q/Q Growth
13.09% -21.40% 161.00% -323.70% 6.61% -31.83% 89.06% -868.79% 5.26% -27.09%
Free Cash Flow Firm Q/Q Growth
-1.62% 8.17% -100.99% -1,253.09% -104.39% -85.42% -80.46% -3.49% 11.11% 28.39%
Invested Capital Q/Q Growth
5.12% 4.62% -35.10% 10.84% 15.71% 37.30% -33.54% 20.74% 8.20% 54.78%
Profitability Metrics
- - - - - - - - - -
Gross Margin
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin
-398.40% -820.37% -266.33% -191.26% -106.50% -8.05% -202.46% -282.88% -559.27% -65.78%
Operating Margin
-407.00% -840.33% -274.04% -197.76% -110.97% -10.60% -209.21% -291.86% -575.24% -69.16%
EBIT Margin
-407.00% -840.33% -274.04% -197.76% -110.97% -10.60% -209.21% -291.86% -575.24% -69.16%
Profit (Net Income) Margin
-400.30% -804.34% -260.10% -188.04% -103.31% -6.30% -199.60% -276.97% -555.20% -63.94%
Tax Burden Percent
100.00% 100.45% 100.00% 100.00% 100.08% 99.30% 100.00% 100.00% 100.00% 101.61%
Interest Burden Percent
98.35% 95.29% 94.91% 95.09% 93.02% 59.90% 95.40% 94.90% 96.52% 90.98%
Effective Tax Rate
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)
-105.40% -134.49% -187.82% -272.38% -428.87% -129.63% -197.34% -392.69% -102.63% -48.16%
Cash Return on Invested Capital (CROIC)
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)
-13.35% -46.90% -25.55% -35.93% -34.24% -4.90% -109.76% -188.04% -205.40% -13.44%
Return on Assets (ROA)
-13.13% -44.89% -24.25% -34.17% -31.87% -2.92% -104.71% -178.44% -198.25% -12.42%
Return on Common Equity (ROCE)
-105.40% -134.49% -187.82% -272.38% -428.87% -129.63% -197.34% -392.69% -102.63% -48.16%
Return on Equity Simple (ROE_SIMPLE)
-178.19% 0.00% -466.78% -1,070.13% 1,636.02% 0.00% -131.89% -242.96% -49.97% 0.00%
Net Operating Profit after Tax (NOPAT)
-4.53 -5.65 -5.73 -5.42 -4.81 -0.90 -7.19 -8.11 -9.11 -5.39
NOPAT Margin
-284.90% -588.23% -191.83% -138.43% -77.68% -7.42% -146.45% -204.31% -402.67% -48.41%
Net Nonoperating Expense Percent (NNEP)
-4.37% -5.94% -4.20% -4.70% -4.64% 0.35% -6.61% -9.50% -6.46% -1.81%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - -3.97% - - - -3.70%
Cost of Revenue to Revenue
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue
161.16% 291.12% 117.52% 72.68% 48.84% 28.37% 82.98% 77.00% 153.15% 38.39%
R&D to Revenue
345.85% 649.21% 256.52% 225.08% 162.13% 82.23% 226.23% 314.87% 522.09% 130.77%
Operating Expenses to Revenue
507.00% 943.90% 374.04% 297.76% 211.06% 110.61% 309.21% 391.86% 675.24% 170.17%
Earnings before Interest and Taxes (EBIT)
-6.48 -8.07 -8.18 -7.75 -6.86 -1.28 -10 -12 -13 -7.70
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-6.34 -7.87 -7.95 -7.49 -6.59 -0.97 -9.93 -11 -13 -7.32
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
9.47 8.27 17.17 44.23 0.00 6.66 11.57 13.19 7.25 4.31
Price to Tangible Book Value (P/TBV)
9.47 8.27 17.17 44.23 0.00 6.66 11.57 13.19 7.25 4.31
Price to Revenue (P/Rev)
91.78 38.19 19.24 12.77 6.27 5.98 7.87 5.59 21.31 28.18
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)
64.62 23.28 11.70 9.13 4.48 4.41 6.52 4.63 17.79 21.37
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
16.61 12.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
25.08 10.61 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.22 0.29 0.54 1.24 -1.89 0.00 0.18 0.29 0.05 0.00
Long-Term Debt to Equity
0.22 0.29 0.54 1.24 -1.89 0.00 0.18 0.29 0.05 0.00
Financial Leverage
-1.61 -1.62 -3.14 -3.85 -5.01 -2.26 -3.20 -4.27 -1.61 -1.14
Leverage Ratio
1.86 2.12 3.85 4.85 6.68 3.16 4.19 5.92 1.96 1.36
Compound Leverage Factor
1.83 2.02 3.65 4.61 6.21 1.90 4.00 5.62 1.89 1.24
Debt to Total Capital
17.96% 22.27% 35.23% 55.28% 212.53% 0.00% 15.48% 22.69% 4.71% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
17.96% 22.27% 35.23% 55.28% 212.53% 0.00% 15.48% 22.69% 4.71% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
82.04% 77.73% 64.77% 44.72% -112.53% 100.00% 84.52% 77.31% 95.29% 100.00%
Debt to EBITDA
-0.12 -0.12 -0.11 -0.11 -0.11 0.00 -0.14 -0.12 -0.10 0.00
Net Debt to EBITDA
1.57 1.31 1.42 1.16 0.84 0.00 1.46 0.91 2.35 0.00
Long-Term Debt to EBITDA
-0.12 -0.12 -0.11 -0.11 -0.11 0.00 -0.14 -0.12 -0.10 0.00
Debt to NOPAT
-0.17 -0.16 -0.16 -0.16 -0.16 0.00 -0.18 -0.16 -0.13 0.00
Net Debt to NOPAT
2.21 1.83 1.99 1.61 1.16 0.00 2.00 1.24 3.23 0.00
Long-Term Debt to NOPAT
-0.17 -0.16 -0.16 -0.16 -0.16 0.00 -0.18 -0.16 -0.13 0.00
Altman Z-Score
-0.91 -2.32 -2.61 -3.21 -4.96 -0.54 -0.44 -3.22 9.76 14.39
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
2.05 1.82 1.25 1.11 0.90 1.63 1.57 1.37 4.19 7.77
Quick Ratio
2.01 1.76 1.22 1.08 0.87 1.26 1.51 1.32 4.15 7.21
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
19 21 -0.21 -2.78 -5.68 -11 -25 -25 -23 -16
Operating Cash Flow to CapEx
-1,019.61% -994.47% 1,210.87% -6,931.29% -3,263.47% -2,075.54% -208.42% -20,365.43% -127,309.72% -3,027.08%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.03 0.06 0.09 0.18 0.31 0.46 0.52 0.64 0.36 0.19
Accounts Receivable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover
0.62 0.80 1.55 2.55 3.22 4.96 5.06 5.22 4.44 4.00
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
-28 -27 -36 -32 -27 -17 -18 -15 -13 -6.05
Invested Capital Turnover
-0.10 -0.19 -0.17 -0.31 -0.51 -1.16 -1.00 -1.17 -1.15 -1.94
Increase / (Decrease) in Invested Capital
-24 -26 -5.52 -2.64 0.88 9.64 17 17 14 11
Enterprise Value (EV)
103 59 65 86 63 111 177 126 413 476
Market Capitalization
146 97 107 121 88 151 213 152 495 627
Book Value per Share
$0.63 $0.47 $0.25 $0.11 ($0.07) $0.73 $0.59 $0.36 $2.10 $3.20
Tangible Book Value per Share
$0.63 $0.47 $0.25 $0.11 ($0.07) $0.73 $0.59 $0.36 $2.10 $3.20
Total Capital
19 15 9.58 6.11 1.59 23 22 15 72 145
Total Debt
3.38 3.38 3.38 3.38 3.38 0.00 3.38 3.38 3.38 0.00
Total Long-Term Debt
3.38 3.38 3.38 3.38 3.38 0.00 3.38 3.38 3.38 0.00
Net Debt
-43 -38 -42 -34 -25 -39 -37 -26 -82 -152
Capital Expenditures (CapEx)
0.56 0.69 0.35 0.14 0.27 0.56 0.61 0.06 0.01 0.49
Debt-free, Cash-free Net Working Capital (DFCFNWC)
-22 -22 -36 -34 -32 -20 -25 -21 -20 -9.16
Debt-free Net Working Capital (DFNWC)
24 19 9.46 3.77 -3.40 20 15 8.31 65 142
Net Working Capital (NWC)
24 19 9.46 3.77 -3.40 20 15 8.31 65 142
Net Nonoperating Expense (NNE)
1.84 2.07 2.04 1.94 1.59 -0.13 2.61 2.89 3.45 1.73
Net Nonoperating Obligations (NNO)
-43 -38 -42 -35 -25 -39 -37 -26 -82 -152
Total Depreciation and Amortization (D&A)
0.14 0.19 0.23 0.25 0.28 0.31 0.33 0.36 0.36 0.38
Debt-free, Cash-free Net Working Capital to Revenue
-1,401.34% -866.92% -644.79% -359.81% -227.19% -79.05% -91.85% -77.89% -84.73% -41.12%
Debt-free Net Working Capital to Revenue
1,527.44% 756.51% 170.86% 39.88% -24.19% 77.79% 55.46% 30.62% 281.33% 639.23%
Net Working Capital to Revenue
1,527.44% 756.51% 170.86% 39.88% -24.19% 77.79% 55.46% 30.62% 281.33% 639.23%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
($0.26) ($0.31) ($0.31) ($0.29) ($0.25) $0.02 ($0.31) ($0.35) ($0.38) ($0.11)
Adjusted Weighted Average Basic Shares Outstanding
24.43M 24.55M 25.25M 25.34M 25.82M 26.78M 31.35M 31.84M 33.09M 35.22M
Adjusted Diluted Earnings per Share
($0.26) ($0.31) ($0.31) ($0.29) ($0.25) $0.02 ($0.31) ($0.35) ($0.38) ($0.11)
Adjusted Weighted Average Diluted Shares Outstanding
24.43M 24.55M 25.25M 25.34M 25.82M 26.78M 31.35M 31.84M 33.09M 35.22M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
25.24M 25.26M 25.27M 25.78M 30.79M 31.40M 31.81M 32.54M 45.47M 45.68M
Normalized Net Operating Profit after Tax (NOPAT)
-4.53 -5.65 -5.73 -5.42 -4.80 -0.90 -7.19 -8.11 -9.11 -5.39
Normalized NOPAT Margin
-284.90% -588.23% -191.83% -138.43% -77.62% -7.42% -146.45% -204.31% -402.67% -48.41%
Pre Tax Income Margin
-400.30% -800.77% -260.10% -188.04% -103.22% -6.35% -199.60% -276.97% -555.20% -62.92%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Capricor Therapeutics' Financials

When does Capricor Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Capricor Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Capricor Therapeutics' net income changed over the last 2 years?

Capricor Therapeutics' net income appears to be on an upward trend, with a most recent value of -$40.47 million in 2024, rising from -$29.02 million in 2022. The previous period was -$22.29 million in 2023.

What is Capricor Therapeutics's operating income?
Capricor Therapeutics's total operating income in 2024 was -$42.56 million, based on the following breakdown:
  • Total Gross Profit: $22.27 million
  • Total Operating Expenses: $64.95 million
How has Capricor Therapeutics revenue changed over the last 2 years?

Over the last 2 years, Capricor Therapeutics' total revenue changed from $2.55 million in 2022 to $22.27 million in 2024, a change of 772.8%.

How much debt does Capricor Therapeutics have?

Capricor Therapeutics' total liabilities were at $25.02 million at the end of 2024, a 30.8% decrease from 2023, and a 34.7% decrease since 2022.

How much cash does Capricor Therapeutics have?

In the past 2 years, Capricor Therapeutics' cash and equivalents has ranged from $9.60 million in 2022 to $14.69 million in 2023, and is currently $11.29 million as of their latest financial filing in 2024.

How has Capricor Therapeutics' book value per share changed over the last 2 years?

Over the last 2 years, Capricor Therapeutics' book value per share changed from 0.47 in 2022 to 3.20 in 2024, a change of 585.2%.



This page (NASDAQ:CAPR) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners